Alongside diabetes, Novo Nordisk 'poised for top spot in hemophilia'
This article was originally published in Scrip
Executive Summary
Not satisfied by being world's top diabetes company, Novo Nordisk is set to become the market leader in hemophilia as it builds on its leadership position in the factor VIIa segment and branches out with new offerings for hemophilia A and hemophilia B. This is the conclusion of a new report published by Datamonitor Healthcare entitled Key Companies in Hemophilia.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.